Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

Radiotherapy 9Doxorubicin 7pazopanib 5palbociclib 4Trabectedin 4Gemcitabine 4ribociclib 3pembrolizumab 3eribulin 3Magnetic Resonance Spectroscopy 3selinexor 2liposomal doxorubicin 2avelumab 2abemaciclib 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Immunoglobulin G 2Ifosfamide 2Docetaxel 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1sotigalimab 1sodium thiosulfate 1sitravatinib 1silmitasertib 1sargramostim 1romidepsin 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liposarcoma × Nivolumab × Clear all
NCT03307616 2026-03-05

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡